Twist Bioscience Corporation (TWST)
| Market Cap | 3.10B +35.6% |
| Revenue (ttm) | 409.48M +17.8% |
| Net Income | -81.28M |
| EPS | -1.34 |
| Shares Out | 62.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 378,504 |
| Open | 51.31 |
| Previous Close | 52.95 |
| Day's Range | 49.84 - 52.65 |
| 52-Week Range | 23.30 - 66.06 |
| Beta | 2.23 |
| Analysts | Buy |
| Price Target | 53.44 (+7.4%) |
| Earnings Date | May 4, 2026 |
About TWST
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ... [Read more]
Financial Performance
In fiscal year 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for TWST stock is "Buy." The 12-month stock price target is $53.44, which is an increase of 7.40% from the latest price.
News
LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery
DÜSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience...
Twist Bioscience announces inducement grants under Nasdaq listing rule
Twist Bioscience (TWST) announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units and up to 13,348 performance stock units, will be granted to 53 recently…
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value bi...
Twist Bioscience price target raised to $60 from $55 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Twist Bioscience (TWST) to $60 from $55 and keeps a Buy rating on the shares. The firm adjusted estimates following…
Twist Bioscience price target raised to $65 from $50 at Baird
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Twist Bioscience (TWST) to $65 from $50 and keeps an Outperform rating on the shares. The firm updated its…
Twist Bioscience upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Twist Bioscience (TWST) to Outperform from Market Perform with a $70 price target
Twist Bioscience price target raised to $65 from $55 at Barclays
Barclays raised the firm’s price target on Twist Bioscience (TWST) to $65 from $55 and keeps an Overweight rating on the shares. The company reported solid results “across the board,”…
Twist Bioscience Earnings Call Transcript: Q2 2026
Q2 revenue grew 19% YoY to $110.7M, with gross margin expanding to 51.6% and strong growth in DNA synthesis, protein solutions, and NGS. Fiscal 2026 guidance was raised, with adjusted EBITDA breakeven expected in Q4, driven by robust demand in AI-enabled drug discovery and diagnostics.
Twist Bioscience sees Q3 revenue $114M-$115M, consensus $111.27M
The company said, ” As previously discussed, we expect NGS to be the driver of sequential growth in H2 and return to 20% growth by 4Q.”
Twist Bioscience expects to achieve adjusted EBITDA breakeven for Q4
07:22 EDT Twist Bioscience (TWST) expects to achieve adjusted EBITDA breakeven for Q4
Twist Bioscience expands clonal genes portfolio with Complex Genes
Twist Bioscience (TWST) expanded its clonal genes portfolio with the early access launch of Complex Genes. Sequences with complex elements have historically been difficult to produce at commercial sca...
Twist Bioscience reports Q2 EPS (71c) vs. (66c) last year
Reports Q2 revenue $110.7M, consensus $107.66M. “We had a strong performance in the first half of fiscal 2026, ending the second quarter with our thirteenth consecutive quarter of growth. Revenue…
Twist Bioscience raises FY26 revenue view $442M-$447M from $435M-$440M
Consensus $438.75M. Gross margin to be above 52% for fiscal 2026
Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access l...
Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the...
Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the ...
Twist Bioscience price target raised to $55 from $50 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Twist Bioscience (TWST) to $55 from $50 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Twist Bioscience price target raised to $56 from $52 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Twist Bioscience (TWST) to $56 from $52 and keeps an Outperform rating on the shares as part of the…
Twist Bioscience price target raised to $55 from $50 at Guggenheim
Guggenheim raised the firm’s price target on Twist Bioscience (TWST) to $55 from $50 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select…
Twist Bioscience Transcript: Leerink Global Healthcare Conference 2026
Strong growth driven by new product launches, automation, and AI-enabled services has expanded the addressable market and improved margins. Strategic focus on high-throughput solutions, commercial excellence, and a shift to fee-for-service contracts positions the company for continued revenue and margin expansion.
Twist Bioscience Transcript: Barclays 28th Annual Global Healthcare Conference
Resegmentation and AI integration are accelerating growth in DNA synthesis, protein solutions, and drug discovery, with new high-throughput capabilities from the Invenra acquisition. NGS and diagnostics are expanding, driven by innovation in workflow and enzyme engineering, while gross margins continue to improve and capacity is scaling to meet demand.
Twist Bioscience Transcript: TD Cowen 46th Annual Health Care Conference
Management reaffirmed the goal of Adjusted EBITDA breakeven by Q4 FY2026, driven by margin expansion and disciplined OpEx. AI and MRD are fueling rapid growth, with automation and product innovation providing competitive advantages. Long-term, the addressable market is targeted to reach $12B+.
Twist Bioscience Stock (TWST) Tumbles after Senior Executive Offloads $2M in Shares
Shares of Twist Bioscience ($TWST) declined about 8% on Friday morning after an insider sale raised fresh attention from investors. The drop followed a regulatory filing showing that Paula Green,…
Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...
Twist Bioscience enters licensing agreement with Invenra
Twist Bioscience (TWST) announced that it has entered into a licensing agreement with Invenra. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of…